Treatment for acute myeloid leukemia M5, or acute monocytic leukemia, is based on chemotherapy and can also be treated with hematopoietic stem cell transplantation.
Chemotherapy is the main form of treatment for acute monocytic leukemia to try to kill the cancer cells. Chemotherapeutic agents include: anthracyclines (mainly Zoerythromycin, DNR) plus cytarabine (Ara-C) i.e. DA3+7 is the most common international chemotherapy regimen used to induce remission.
Complete resolution of symptoms can be achieved with chemotherapy in 50% to 80% of patients, depending on the age of the patient at the time of diagnosis and the severity of the disease, among other things. However, if treatment is stopped after the first phase of chemotherapy, the leukemia will relapse quickly and the remission period is usually very short.
Different treatments may be used to treat leukemia after remission, such as other chemotherapy regimens or high-dose chemotherapy followed by hematopoietic stem cell transplantation, depending on the patient’s age and the particular biology of the leukemia in question. Treatment after remission can significantly prolong the patient’s life.
If the diagnosis of acute myeloid leukemia M5 is confirmed, the patient should be immediately hospitalized and treated by a specialist physician who will choose the appropriate treatment according to the patient’s specific situation and the stage of the disease, and blind self-medication should be avoided. Drugs need to be used under medical supervision.